BCB-214

BCB-214 is a next-generation chimeric antigen receptor (CAR) T-cell therapy being developed by BrainChild Bio for the treatment of adult glioblastoma and pediatric brain tumors. The therapy utilizes a triple-targeting construct designed to simultaneously recognize three distinct tumor-associated antigens, an approach intended to overcome the challenges of tumor heterogeneity and antigen escape commonly observed in central nervous system (CNS) malignancies. BCB-214 incorporates the company's proprietary PotencyPlus platform, which is engineered to enhance the metabolic fitness, persistence, and effector function of the CAR T-cells within the immunosuppressive brain tumor microenvironment. As of 2026, the program is in the IND-enabling stage, with an Investigational New Drug (IND) application filing projected for 2027.